Star Health Launches 32 Arogya Seva Kendras; to Provide Primary Healthcare Access to over a Million Lives
First Arogya Seva Kendra inaugurated in Egmore, Chennai; Tamil Nadu rollout includes Nagercoil,…
Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock
December 04, 2025 22:05 ET | Source: Symbotic Inc. WILMINGTON, Mass., Dec.…
Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease
October 22, 2025 16:30 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Oct.…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
